Eli Lilly and Company

• LLY Stock Price 24h change: +0.22%. From 1,063.56 USD to 1,065.94 USD. The slight gain was driven by analyst optimism regarding the company's $1 billion AI partnership with Nvidia and reports of a potential €15 billion acquisition of French biotech Abivax.
• From a technical perspective, LLY is in a "long-term bullish, short-term consolidation" phase. The price remains above its 50-day ($1,037) and 200-day ($861) SMAs, confirming a strong primary uptrend, while the 14-day RSI at 52.6 suggests a neutral momentum as the market digests recent gains near the $1,100 resistance level.
• Eli Lilly and Nvidia announced a $1 billion joint investment to launch a co-innovation AI lab in the Bay Area aimed at accelerating drug discovery and scaling medicine production with robotics.
• Reports surfaced that Eli Lilly is preparing a €15 billion offer to acquire French biotech firm Abivax, signaling a strategic push to further diversify its immunology pipeline beyond the GLP-1 market.
• Late-stage clinical data showed that combining Zepbound with Taltz significantly improved symptoms for patients with both obesity and psoriatic arthritis, potentially expanding the label for both blockbuster drugs.
• The FDA announced it will reduce regulatory requirements for manufacturing cell and gene therapies (CGTs) to streamline the market entry process for innovative, small-batch pharmaceutical products.
• J&J revealed a major US drug pricing deal and plans to build two new domestic manufacturing plants, highlighting the industry's focus on supply chain resilience and navigating new federal pricing regulations.

• LLY Stock Price 24h change: -1.99%. From 1,085.19 USD to 1,063.56 USD.
The decline was primarily driven by profit-taking following a recent surge and increased competition in the weight-loss market, notably after Novo Nordisk's aggressive U.S. pricing for its oral Wegovy pill.• From a technical perspective, LLY is in a "short-term corrective phase within a long-term bull market." While the stock recently hit an all-time high of $1,133.95, the RSI has retreated to a neutral 52.19 and the MACD has issued a slight sell signal. The price remains above its 200-day SMA ($861.18), but investors are watching $1,050 as a key psychological support level.• Eli Lilly announced a $1.2 billion acquisition of Ventyx Biosciences to expand its immunology pipeline, signaling a strategic diversification beyond its core obesity and diabetes franchises.• A Phase 3b trial showed that a combination of Zepbound and Taltz significantly improved symptoms for patients with psoriatic arthritis and obesity, potentially expanding the drug's label.• Eli Lilly partnered with Nimbus Therapeutics in a deal worth up to $1.35 billion to develop a new oral obesity treatment, aiming to address "needle fatigue" associated with current injectables.• Novo Nordisk launched its recently FDA-approved oral Wegovy pill in the U.S. with a starting price of $149/month, intensifying the price war in the lucrative GLP-1 weight-loss drug sector.• The S&P 500 Healthcare Index rose 1.5% this week as investors rotated into defensive sectors following tariff reprieves for major drugmakers like Johnson & Johnson.